- UltraShape Is Recognized As A Breakthrough In
Non-Invasive Abdominal Fat Reduction Thanks To Its Painless And
Effective Ultrasound Technology
WAYLAND, Massachusetts,
Jan. 15, 2015 /PRNewswire/ --
Syneron Medical Ltd. (NASDAQ: ELOS), a leading global
aesthetic device company, announced today that NewBeauty
Magazine awarded UltraShape® the "Best Body-Contouring
Treatment" in its annual 2014 Beauty Choice Awards. As a winner in
the coveted "Beauty Game Changers" category, UltraShape is
recognized for its innovative ultrasound-based treatment that
painlessly and permanently destroys fat in the abdominal area where
fat is most resistant to diet and exercise.
Photo - http://photos.prnewswire.com/prnh/20150115/169395
Logo - http://photos.prnewswire.com/prnh/20120528/535447
Featured alongside an elite list of outstanding aesthetic
products, NewBeauty notes that UltraShape was chosen by a panel of
thousands of readers, editors and beauty industry experts for its
ability to deliver real, noticeable and highly customizable results
"without surgery or hours spent in the gym."
"As the number of satisfied UltraShape users continues to grow,
we are honored to earn recognition from NewBeauty Magazine,
further validating our leading position in the body shaping space,"
said Dr. Shimon Eckhouse, Chairman
of the Board of Directors for Syneron. "UltraShape represents the
next generation in body-shaping with proven clinical outcomes and a
superior safety profile, underscoring Syneron's ongoing commitment
to advancing treatment outcomes through technological
innovation."
"What sets UltraShape apart from other body shaping solutions is
its fast outcomes with results visible in often as little as 2
weeks post first treatment," says Amit Meridor, Chief Executive
Officer of Syneron. "With UltraShape's customizable treatments, for
the very first time physicians are able to truly sculpt instead of
bulk heat or freeze fat. UltraShape is a painless solution for
those who cannot get rid of stubborn fat resistant to diet and
exercise."
The UltraShape System is the first and only non-invasive body
shaping treatment that uses pulsed focused ultrasound energy to
precisely target subcutaneous fat, while keeping the surrounding
tissue, vasculature, nerves and muscles intact. Unlike other body
shaping technologies that use heat or freezing techniques,
UltraShape uses a pure mechanical effect to destroy fat cells
without inducing thermal damage. This unique feature of UltraShape
technology results in a safe and comfortable treatment experience
with no visible signs of treatment and no downtime.
The newest fat-blasting treatment on the block, UltraShape, with
over 300,000 procedures performed worldwide, was cleared by the
United States Food and Drug Administration (FDA) 510(k) for
non-invasive reduction of abdominal circumference via fat cell
destruction in April of last year.
About NewBeauty
NewBeauty® magazine is the
definitive authority on all things beauty. Each issue
of NewBeauty gives readers an in-depth look at the
beauty industry's latest products, cutting-edge innovations and
breakthrough technologies. Whether it's the latest high-powered
skin care or in-office
procedure, NewBeauty educates readers on the
latest options for skin, face, hair, body, well-being and smile.
The magazine's comprehensive approach to its topics continues to
solidify its reputation as the industry's leading scientifically
accurate, expert-driven and ethically balanced beauty
resource.
About Syneron Candela:
Syneron Candela is a leading global aesthetic device company
with a comprehensive product portfolio and a global distribution
footprint. The Company's technology enables physicians to
provide advanced solutions for a broad range of medical-aesthetic
applications including body contouring, hair removal, wrinkle
reduction, tattoo removal, improving the skin's appearance through
the treatment of superficial benign vascular and pigmented lesions,
and the treatment of acne, leg veins and cellulite. The Company
sells its products under three distinct brands, Syneron, Candela
and CoolTouch, and has a wide portfolio of trusted, leading
products including UltraShape, VelaShape, GentleLase, VBeam
Perfecta, PicoWay and elos Plus.
Founded in 2000, the corporate, R&D, and manufacturing
headquarters for Syneron Candela are located in Israel. Syneron Candela also has R&D and
manufacturing operations in the U.S. The company markets,
services and supports its products in 86 countries. It has
offices in North America,
France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan,
and Hong Kong and distributors
worldwide.
For additional information, please visit
http://www.syneron-candela.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties. Such forward-looking
statements include the expectations, plans and prospects for the
Company, including product efficacy, market acceptance of new
products, and projected revenues, margins, earnings and market
shares. The statements made by the Company are based upon
management's current expectations and are subject to certain risks
and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include the risk factors and
other cautionary statements described in the Company's filings with
the SEC, including those described in the Company's most recent
Annual Report on Form 20-F, and in the filings that Syneron Medical
makes with the SEC, and other factors beyond the Company's control.
If one or more of these factors materialize, or if any underlying
assumptions prove incorrect, Syneron Medical Ltd.'s actual results,
performance or achievements may vary materially from those
expressed or implied by these forward-looking statements.
These forward-looking statements should not be relied upon as
representing Syneron Medical Ltd.'s views as of any date after the
date of this document. The Company does not intend to update these
statements and undertakes no duty to any person to provide any such
update under any circumstance.
Additional information can be found
at www.syneron-candela.com
KELZ PR - +1-646-450-5359
Patty Mathews –
pattymathews@kelzpr.com
Melissa Ben-Yoseph -
Melissa@kelzpr.com
Zack Kubow, The Ruth Group
zkubow@theruthgroup.com, +1-646-536-7020
Hugo Goldman, Chief Financial
Officer, Syneron Hugo.Goldman@syneron.com
Syneron Medical Public Relations pr@syneron.com